Yan-Ping Mao

2.5k citations
2 papers · 417 indexed · 1 hit paper · h-index 2
Topics
RNA Interference and Gene Delivery (1 paper)Cancer Immunotherapy and Biomarkers (1 paper)Lung Cancer Research Studies (1 paper)
Partner nations
ChinaTaiwan

In The Last Decade

Yan-Ping Mao

2 papers receiving 413 citations

Hit Papers

Comparative safety of immune checkpoint inhibitors in can...20182026202020232018100200300400

Peers

Yan-Ping Mao
Comparison fields: 5 of 55
  • Oncology 364
  • Pulmonary and Respiratory Medicine 125
  • Immunology 94
  • Surgery 52
  • Molecular Biology 34
Replace Eriko Murakami with:
Eriko Murakami Japan
Alyx Rosen United States
Jeryl Villadolid United States
Pierre‐Marie Morice France
Benjamin Benhuri United States
Depei Huang China
Khalid Jazieh United States
Sara Alcántara Luna Spain
R. Mauritz Netherlands
Yan-Ping Mao relative to Eriko Murakami Japan Eriko Murakami's profile →
Citations per field
00.5×1.5×2.4×
Eriko Murakami · 1×
Citations per year

Countries citing papers authored by Yan-Ping Mao

Since Specialization
Citations

This map shows the geographic impact of Yan-Ping Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan-Ping Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan-Ping Mao more than expected).

Fields of papers citing papers by Yan-Ping Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan-Ping Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan-Ping Mao. The network helps show where Yan-Ping Mao may publish in the future.

Co-authorship network of co-authors of Yan-Ping Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Yan-Ping Mao. A scholar is included among the top collaborators of Yan-Ping Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan-Ping Mao. Yan-Ping Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

2 of 2 papers shown
#WorkIndexed citations
1 1
2
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysisbreakdown →
416

About Yan-Ping Mao

Yan-Ping Mao is a scholar working on Otorhinolaryngology, Oncology and Surgery, having authored 2 papers that have together received 417 indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (1 paper), Cancer Immunotherapy and Biomarkers (1 paper) and Lung Cancer Research Studies (1 paper). The work is most often cited by research in Oncology (364 citations), Immunology (94 citations) and Pulmonary and Respiratory Medicine (125 citations). Yan-Ping Mao has collaborated with scholars based in China and Taiwan. Frequent co-authors include Chiun Hsu, Xiao-Jing Du, Qing Liu, Ai-Hua Lin, Ling‐Long Tang, Cheng Xu, Yu‐Pei Chen, Lei Chen, Wen-Fei Li and Jun Ma. Their work appears in journals such as Journal of Clinical Oncology and BMJ.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026